MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Alcon Inc

Затворен

СекторЗдравеопазване

92.5 -0.03

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

91.56

Максимум

92.68

Ключови измерители

By Trading Economics

Приходи

21M

284M

Продажби

48M

2.5B

P/E

Средно за сектора

46.307

63.778

EPS

0.72

Дивидентна доходност

0.28

Марж на печалбата

11.351

Служители

25,599

EBITDA

56M

397M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+15.91% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.28%

2.39%

Следващи печалби

13.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

5.9B

47B

Предишно отваряне

92.53

Предишно затваряне

92.5

Настроения в новините

By Acuity

50%

50%

180 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Alcon Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.03.2025 г., 21:22 ч. UTC

Придобивния, сливания и поглъщания

Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment

24.03.2025 г., 12:36 ч. UTC

Придобивния, сливания и поглъщания

Alcon to Buy Lensar in Deal Worth Up to $430 Million

12.11.2024 г., 18:48 ч. UTC

Печалби
Значими двигатели на пазара

Alcon Posts Higher 3Q Sales and Profit, Lowers 2024 Sales View

26.03.2025 г., 21:55 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk

26.03.2025 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

Aurion Board Appoints Arnaud Lacoste as CEO of Aurion

26.03.2025 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

Alcon: Aurion Will Operate as a Separate Company With Full Support From Alcon to Advance Its Clinical-Stage Allogeneic Cell Therapy Asset

26.03.2025 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

Leverages Alcon's Global Scale With Aurion's Cell Therapy Expertise to Accelerate U.S. Phase 3 Development in Fall of 2025 >ALC.EB

26.03.2025 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

Alcon Acquires Interest in Aurion to Advance Innovative Cell Therapy for Corneal Endothelial Disease >ALC.EB

26.03.2025 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

Alcon Inc. Unit Alcon Research Previously Sued Aurion to Prevent It From Going Public

26.03.2025 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

Alcon Acquires Majority Interest in Aurion Biotech >ALC.EB

26.03.2025 г., 20:30 ч. UTC

Придобивния, сливания и поглъщания

Alcon Acquires Majority Interest in Aurion Biotech

24.03.2025 г., 12:21 ч. UTC

Придобивния, сливания и поглъщания

Alcon to Buy Lensar in Deal Worth Up to $430M

24.03.2025 г., 12:05 ч. UTC

Придобивния, сливания и поглъщания

Alcon: Transaction Is Anticipated to Close in Mid-To-Late 2025 >ALC

24.03.2025 г., 12:05 ч. UTC

Придобивния, сливания и поглъщания

Alcon: Transaction Represents a Total Consideration of Up to About $430M >ALC

24.03.2025 г., 12:04 ч. UTC

Придобивния, сливания и поглъщания

Alcon: Additional Non-Tradeable Contingent Value Right Offering Up to $2.75 Per Shr in Cash, Conditioned on Achievement of 614,000 Cumulative Procedures With LENSAR's Products Between Jan 1, 2026, and Dec 31, 2027 >ALC

24.03.2025 г., 12:04 ч. UTC

Придобивния, сливания и поглъщания

Alcon Will Purchase All Outstanding Shrs of LENSAR for $14.00 Per Shr in Cash >ALC

24.03.2025 г., 12:03 ч. UTC

Придобивния, сливания и поглъщания

Alcon: Acquisition Includes ALLY Robotic Cataract Laser Treatment System, LENSAR's Proprietary Streamline Software Technology and LENSAR Legacy Laser System >ALC

24.03.2025 г., 12:03 ч. UTC

Придобивния, сливания и поглъщания

Alcon Agrees to Acquire LENSAR >ALC

24.03.2025 г., 12:00 ч. UTC

Придобивния, сливания и поглъщания

Alcon Agrees To Acquire LENSAR, Inc. >ALC LNSR

25.02.2025 г., 21:33 ч. UTC

Печалби

Alcon Sees 2025 Adj EPS $3.15-Adj EPS $3.25 >ALC.EB

25.02.2025 г., 21:33 ч. UTC

Печалби

Alcon Sees 2025 Sales $10.2B-$10.4B >ALC.EB

25.02.2025 г., 21:32 ч. UTC

Печалби

Alcon: Board Authorized the Repurchase of Up to $750M of the Company's Common Shrs >ALC.EB

25.02.2025 г., 21:31 ч. UTC

Печалби

Alcon 4Q EPS 57c >ALC.EB

25.02.2025 г., 21:31 ч. UTC

Печалби

Alcon 4Q Rev $2.5B >ALC.EB

17.12.2024 г., 15:05 ч. UTC

Пазарно говорене

Alcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk

12.11.2024 г., 17:38 ч. UTC

Печалби

Alcon Narrows 2024 View To Adj EPS $3.00-Adj EPS $3.05 >ALC

12.11.2024 г., 17:38 ч. UTC

Печалби

Alcon Had Seen 2024 Sales $9.9B-$10.1B >ALC

12.11.2024 г., 17:37 ч. UTC

Печалби

Alcon Cuts 2024 View To Sales $9.8B-$9.9B >ALC

12.11.2024 г., 17:36 ч. UTC

Печалби

Alcon 3Q Core Operating Margin 20.6% >ALC

12.11.2024 г., 17:36 ч. UTC

Печалби

Alcon 3Q Sales $2.43B >ALC

Сравнение с други в отрасъла

Ценова промяна

Alcon Inc Прогноза

Ценова цел

By TipRanks

15.91% нагоре

12-месечна прогноза

Среден 107.45 USD  15.91%

Висок 120 USD

Нисък 90 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Alcon Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

20 ratings

18

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

90.87 / 92.61Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

180 / 386 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Alcon Inc

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.